VivaCell Biotechnology España SL is a privately held, preclinical-stage pharmaceutical company based in Córdoba, Spain. VivaCell is worldwide pioneer in the discovery and development of cannabidiol and cannabigerol new derivatives for the treatment of inflammatory and neurodegenerative diseases.
Our preclinical development pipeline is focused on unmet medical needs in the treatment of serious life-threatening conditions. Two preclinical candidates are highlighted (VCE-004.8 and VCE-003.2) for the treatment of Multiple Sclerosis, Huntington's Disease and Scleroderma. Additonally, we are developing a hemp phytoextract (CDE-001) for the improvement of skin conditions such as Atopic Dermatitis.